Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents.
Anne M KerolaSilvia RollefstadA KazemiG WibetoeJ SextonNina J MarsMarkku KauppiTore K KvienEspen A HaavardsholmAnne Grete SembPublished in: Scandinavian journal of rheumatology (2022)
In Norway, the combined prevalence of PsA, axSpA, and RA was over 1.5%. Reflecting the good overall access to highly effective but costly biologic treatments, more than a fourth of these patients used biologic agents, which corresponds to over 0.4% of Norwegian adult population.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- end stage renal disease
- risk factors
- prostate cancer
- interstitial lung disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- systemic lupus erythematosus
- patient reported outcomes
- radical prostatectomy
- cross sectional